ICON'S Firecrest Training Recognized by TransCelerate
ICON announced that TransCelerate has certified its Firecrest GCP training as mutually acceptable for its members.
ICON announced that TransCelerate has certified that its Firecrest GCP training is mutually acceptable for its members. Under this TransCelerate initiative, investigators completing the training will avoid having to repeatedly complete pre-qualification GCP training for every trial. According to ICON, its Firecrest training has some features not available in other training programs, which include the ability for sponsors to assign training requirements per specific job role; track training compliance and notify users of overdue training or re-certification due dates; and enhanced reporting capabilities to analyze and report completion metrics at a region, site or role level.
Read the full release here.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
